Click here to read: In-depth report on antihypertensive drugs: "Silent killer" gives rise to a huge market (1)
II. Growth of Chinese antihypertensive drug market is faster than that of global market, and the import substitution is expected to speed up under the new policy
2.1 Size of global antihypertensive drug market declines, but the demand dose not
From the perspective of the international market, the antihypertensive drug market peaked at USD 54.9 billion in 2010, and the market size has declined year by year thereafter, for which the main reason lies in the patent expiration of original blockbuster antihypertensive drugs in our opinion, for example, losartan/hydrochlorothiazide, losartan potassium/losartan potassium, and eprosartan mesylate, etc. become off-patent around 2010; the generic drugs marketed at low prices have pushed overall antihypertensive drug prices lower, thereby leading to the decline of size of the antihypertensive drug market.
Chart 9 Size of global antihypertensive drug market in 2008-2014

Data source: South Medicine Economic Research Institute, Fortune Securities
The overall market size of antihypertensive drugs has declined after 2010, however, this does not mean the decline of demand for antihypertensive drugs. Seen from situation of the mainstream sartan antihypertensive drugs at present, the overall market size of sartan drugs is declining, however, the demand for sartan drug APIs increases year by year. The demand for antihypertensive drugs is rising, however, the change of structure of drug use (more people select generic drugs with lower prices to substitute original drugs) leads to decline of market sales, but this is good for generic drug manufacturers and API manufacturers.
Angiotensin II receptor blockers and calcium channel blockers were the main varieties, from the perspective of sales of global antihypertensive drug varieties in 2014. The Diovan and Exforge of Novartis both had good performance.
Chart 12 Global sales situation of some antihypertensive drugs in 2014










(All Rights Reserved)